1. Dyck PJ, Lais AC, Ohta M et al (1975) Chronic infammatory polyradiculoneuropathy. Mayo Clin Proc 50(11):621–637
2. Van den Bergh PY, Hadden RD, Bouche P et al (2010) European Federation of neurological societies/peripheral nerve society guideline on management of chronic infammatory demyelinating polyradiculoneuropathy: report of a joint Task Force of the European Federation of Neurological societies and the peripheral nerve society – frst revision. J Peripher Nerv Syst 15(3):185–195
3. Dalakas MC (2011) Advances in the diagnosis, pathogenesis and treatment of CIDP. Nat Rev Neurol 7(9):507–517
4. Latov N (2014) Diagnosis and treatment of chronic acquired demyelinating polyneuropathies. Nat Rev Neurol 10(8):435–446
5. Bunschoten C, Jacobs BC, Van den Bergh PYK et al (2019) Progress in diagnosis and treatment of chronic infammatory demyelinating polyradiculoneuropathy. Lancet Neurol 18(8):784–794
6. Koike H, Katsuno M (2020) Pathophysiology of chronic infammatory demyelinating polyneuropathy: insights into classifcation and therapeutic strategy. Neurol Ther. https://doi.org/10.1007/ s40120-020-00190-8
7. Ng JK, Malotka J, Kawakami N et al (2012) Neurofascin as a target for autoantibodies in peripheral neuropathies. Neurology 79(23):2241–2248
8. Querol L, Nogales-Gadea G, Rojas-Garcia R et al (2013) Antibodies to contactin-1 in chronic infammatory demyelinating polyneuropathy. Ann Neurol 73(3):370–380
9. Querol L, Nogales-Gadea G, Rojas-Garcia R et al (2014) Neurofascin IgG4 antibodies in CIDP associate with disabling tremor and poor response to IVIg. Neurology 82(10):879–886
10. Doppler K, Appeltshauser L, Wilhelmi K et al (2015) Destruction of paranodal architecture in infammatory neuropathy with anti-contactin-1 autoantibodies. J Neurol Neurosurg Psychiatry 86(7):720–728
11. Miura Y, Devaux JJ, Fukami Y et al (2015) Contactin 1 IgG4 associates to chronic infammatory demyelinating polyneuropathy with sensory ataxia. Brain 138(6):1484–1491
12. Ogata H, Yamasaki R, Hiwatashi A et al (2015) Characterization of IgG4 anti-neurofascin 155 antibody-positive polyneuropathy. Ann Clin Transl Neurol 2(10):960–971
13. Devaux JJ, Miura Y, Fukami Y et al (2016) Neurofascin-155 IgG4 in chronic infammatory demyelinating polyneuropathy. Neurology 86(9):800–807
14. Koike H, Kadoya M, Kaida KI et al (2017) Paranodal dissection in chronic infammatory demyelinating polyneuropathy with antineurofascin-155 and anti-contactin-1 antibodies. J Neurol Neurosurg Psychiatry 88(6):465–473
15. Vallat JM, Yuki N, Sekiguchi K et al (2017) Paranodal lesions in chronic infammatory demyelinating polyneuropathy associated with anti-Neurofascin 155 antibodies. Neuromuscul Disord 27(3):290–293
16. Koike H, Nishi R, Ikeda S et al (2018) Ultrastructural mechanisms of macrophage-induced demyelination in CIDP. Neurology 91(23):1051–1060
17. Iijima M, Yamamoto M, Hirayama M et al (2005) Clinical and electrophysiologic correlates of IVIg responsiveness in CIDP. Neurology 64(8):1471–1475
18. Rajabally YA (2015) Long-term immunoglobulin therapy for chronic infammatory demyelinating polyradiculoneuropathy. Muscle Nerve 51(5):657–661
19. Notturno F, Capasso M, DeLauretis A et al (2009) Glial fbrillary acidic protein as a marker of axonal damage in chronic neuropathies. Muscle Nerve 40(1):50–54
20. Wong AH, Fukami Y, Sudo M et al (2016) Sialylated IgG-Fc: a novel biomarker of chronic infammatory demyelinating polyneuropathy. J Neurol Neurosurg Psychiatry 87(3):275–279
21. Allen JA, Merkies ISJ, Lewis RA (2020) Monitoring clinical course and treatment response in chronic infammatory demyelinating polyneuropathy during routine care: a review of clinical and laboratory assessment measures. JAMA Neurol 77(9):1159–1166
22. Lu CH, Macdonald-Wallis C, Gray E et al (2015) Neuroflament light chain: a prognostic biomarker in amyotrophic lateral sclerosis. Neurology 84(22):2247–2257
23. Steinacker P, Feneberg E, Weishaupt J et al (2016) Neuroflaments in the diagnosis of motoneuron diseases: a prospective study on 455 patients. J Neurol Neurosurg Psychiatry 87(1):12–20
24. Preische O, Schultz SA, Apel A et al (2019) Serum neuroflament dynamics predicts neurodegeneration and clinical progression in presymptomatic Alzheimer’s disease. Nat Med 25(2):277–283
25. Mattsson N, Andreasson U, Zetterberg H et al (2017) Alzheimer’s disease neuroimaging initiative. Association of plasma neuroflament light with neurodegeneration in with alzheimer disease. JAMA Neurol 74(5):557–566
26. Lycke JN, Karlsson JE, Andersen O et al (1998) Neuroflament protein in cerebrospinal fuid: a potential marker of activity in multiple sclerosis. J Neurol Neurosurg Psychiatry 64(3):402–404
27. Malmeström C, Haghighi S, Rosengren L et al (2003) Neuroflament light protein and glial fbrillary acidic protein as biological markers in MS. Neurology 61(12):1720–1725
28. Gunnarsson M, Malmeström C, Axelsson M et al (2011) Axonal damage in relapsing multiple sclerosis is markedly reduced by natalizumab. Ann Neurol 69(1):83–89
29. Kuhle J, Kropshofer H, Haering DA et al (2019) Blood neuroflament light chain as a biomarker of MS disease activity and treatment response. Neurology 92(10):e1007–e1015
30. Sandelius Å, Zetterberg H, Blennow K et al (2018) Plasma neuroflament light chain concentration in the inherited peripheral neuropathies. Neurology 90(6):e518–e524
31. Mariotto S, Farinazzo A, Magliozzi R et al (2018) Serum and cerebrospinal neuroflament light chain levels in patients with acquired peripheral neuropathies. J Peripher Nerv Syst 23(3):174–177
32. van Lieverloo GGA, Wieske L, Verhamme C et al (2019) Serum neuroflament light chain in chronic infammatory demyelinating polyneuropathy. J Peripher Nerv Syst 24(2):187–194
33. Ikeda S, Koike H, Nishi R et al (2019) Clinicopathological characteristics of subtypes of chronic infammatory demyelinating polyradiculoneuropathy. J Neurol Neurosurg Psychiatry 90(9):988–996
34. Dyck PJ, Dyck PJB, Engelstad J (2005) Pathologic alterations of nerves. In: Dyck PJ, Thomas PK (eds) Peripheral neuropathy, 4th edn. Elsevier, pp 733–829
35. Gafson AR, Barthélemy NR, Bomont P et al (2020) Neuroflaments: neurobiological foundations for biomarker applications. Brain 143(7):1975–1998
36. Lombardi V, Querin G, Zif OJ et al (2019) Muscle and not neuronal biomarkers correlate with severity in spinal and bulbar muscular atrophy. Neurology 92(11):e1205–e1211
37. Kapoor M, Foiani M, Heslegrave A et al (2019) Plasma neuroflament light chain concentration is increased and correlates with the severity of neuropathy in hereditary transthyretin amyloidosis. J Peripher Nerv Syst 24(4):314–319
38. Shimizu F, Sawai S, Sano Y et al (2014) Severity and patterns of blood-nerve barrier breakdown in patients with chronic infammatory demyelinating polyradiculoneuropathy: correlations with clinical subtypes. PLoS ONE 9(8):e104205
39. Mariotto S, Carta S, Bozzetti S et al (2020) Sural nerve biopsy: current role and comparison with serum neuroflament light chain levels. J Neurol 267(10):2881–2887
40. Fujita A, Ogata H, Yamasaki R et al (2018) Parallel fuctuation of anti-neurofascin 155 antibody levels with clinico-electrophysiological fndings in patients with chronic infammatory demyelinating polyradiculoneuropathy. J Neurol Sci 384:107–112
41. Shimizu S, Iijima M, Fukami Y et al (2020) Efcacy and safety of rituximab in refractory CIDP with or without IgG4 autoantibodies (RECIPE): protocol for a double-blind, randomized PlaceboControlled Clinical Trial. JMIR Res Protoc 9(4):e17117